PPARgamma, Glucose Metabolism, and Cognitive Decline

Peroxisome proliferator-activated receptor gamma (PPAR-γ or PPARG) aka the glitazone receptor is a nuclear receptor that regulates adipose tissue and glucose metabolism. It is increasingly appreciated that the pathophysiology of Alzheimer’s disease involves micro-glial activation and neuroinflammation, dysregulated lipid metabolism as well as glucose homeostasis. For example, some scientists have referred to Alzheimer’s disease as […]

BDNF and Nootropics

Brain-Derived Neurotrophic Factor (BDNF) plays a well-characterized role in synaptic plasticity, neuronal survival, neurogenesis, and resilience to depression and other neuropsychiatric disorders. Most importantly, BDNF provides trophic support for existing neurons while encouraging the reorganization, growth and regeneration of new neurons and synapses. BDNF is an endogenous neuropeptide that activates the TrkB receptor, and is […]

BACE1 Inhibitors Under Development for Alzheimer’s Disease

β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the beta-secratase enzyme required for the production of beta-amyloid, the neurotoxic peptide implicated in Alzheimer’s disease (AD). The extracellular aggregation of amyloid beta represents one of the two pathognomonic features AD, the other being tau hyperphosphorylation. Others scientists, have speculated that beta-amyloid may be an epiphenomenon […]

Nicotinic Receptors as a Nootropic Target

nicotinic acetylcholine receptors

The alpha-7 nicotinic receptor, a type of nicotinic receptor comprised entirely of alpha7 subunits, is implicated in long term and working memory. A number of alpha7 nicotinic acetylcholine receptor agonists are under clinical development for the treatment of schizophrenia and alzheimer’s disease. Nicotine and Schizophrenia Alpha7 nicotinic receptor stimulation likely underlies the cognitive enhancing effects […]

5-HT6 Receptor Antagonists as Novel Nootropics

The 5-HT6 receptor is a subtype of the serotonin receptor that is present almost exclusively in the brain. Preclinical studies have revealed cognitive enhancing effects of 5-HT6 antagonists, even in healthy animals. Currently, numerous 5-HT6 antagonists are under clinical development for the treatment of neurodegenerative disease. [su_button url=”https://www.bluebrainboost.com/wp-content/uploads/2015/08/5-HT6-Receptor-Antagonists-as-Novel-Cognitive-Enhancing-Agents-for-Alzheimer’s-Disease.pdf” background=”#114B5F” color=”#E4FDE1″ icon=”https://www.bluebrainboost.com/wp-content/uploads/2015/08/file148.png” icon_color=”#E4FDE1″]Download PubMed Article PDF [/su_button][su_spacer size=”20″] […]